8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):   February 25, 2004

IMMERSION CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	000-27969	94-3180138
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

801 Fox Lane
San Jose, California 95131
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code:   (408) 467-1900

Not Applicable
(Former name or former address, if changed since last report)

TABLE OF CONTENTS

	Item 5. Other Events and Regulation FD Disclosure
	Item 7. Financial Statements and Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

Item 5. Other Events and Regulation FD Disclosure

     On February 25, 2004, Immersion Corporation entered into an employment agreement with Richard Vogel whereby Mr. Vogel will be appointed the Senior Vice President-General Manager of Immersion Medical effective March 1, 2004. Attached as an exhibit is a press release announcing the appointment of Mr. Vogel.

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit No.	Description
99.1	Press Release dated February 27, 2004 announcing the appointment of Richard Vogel as Immersion’s Senior Vice President-General Manager, Immersion Medical.

     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMERSION CORPORATION
Date:  February 27, 2004	By:	/s/ Victor Viegas
		Victor Viegas
		President, Chief Executive Officer, Chief
		Operating Officer, Chief Financial Officer
		and Director

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated February 27, 2004 announcing the appointment of Richard Vogel as Immersion’s Senior Vice President-General Manager, Immersion Medical.

EX-99.1

[IMMERSION LETTERHEAD]




Contacts:
Gayle Schaeffer
Immersion Corporation
408.350.8778
gschaeffer@immersion.com


         IMMERSION NAMES RICHARD VOGEL AS SENIOR VICE PRESIDENT/GENERAL
                          MANAGER OF IMMERSION MEDICAL

SAN JOSE, CALIF., FEBRUARY 27, 2004 (BUSINESS WIRE) -- Immersion Corporation
(Nasdaq: IMMR), a leading developer and licensor of touch feedback technology,
today announced the appointment of Richard Vogel as senior vice president and
general manager of its wholly-owned subsidiary, Immersion Medical, Gaithersburg,
Maryland, effective March 1. Vogel will report to Immersion President and Chief
Executive Officer Victor Viegas.

"Richard Vogel brings market-driven leadership and a passion for building
medical businesses to Immersion Medical," says Victor Viegas, president and CEO
of Immersion. "He has a proven track record of commercializing products,
building distribution channels and strategic alliances, and expanding
international sales."

Previously, Vogel has held CEO/president/COO and general manager positions at a
variety of medical device, durable medical equipment, and capital equipment
companies. Over his 25-year career, Vogel has profitably grown medical start-ups
as well as the medical businesses of public companies such as Kinetic Concepts,
Inc. and American Cyanamid. Vogel holds a Bachelor of Arts degree from
Middlebury College in Vermont and a master's degree in business administration
from Harvard Business School. He speaks five languages and has extensive
international experience including assignments in various locations in Europe
and South America.

Pursuant to the terms of Vogel's employment agreement, Immersion has agreed to
grant inducement stock options, subject to approval by Immersion's Board of
Directors, effective as of the date of Vogel's commencement of employment. These
options will be granted without stockholder approval pursuant to Nasdaq
Marketplace Rule 4350(i)(1)(A)(iv) under the following terms: 200,000 stock
options, which shall be treated as nonstatutory stock options, an exercise price
equal to the closing price of Immersion's stock as reported on the Nasdaq
National Market on the date of Vogel's commencement of employment and vesting
over four years, with 25 percent of the shares



vesting on the one year anniversary of the employment commencement date, and
with an additional 2.083 percent of the options vesting per month of service
thereafter.

ABOUT IMMERSION (WWW.IMMERSION.COM)

Founded in 1993, Immersion Corporation is a recognized leader in developing,
licensing, and marketing digital touch technology and products. Bringing value
to markets where man-machine interaction needs to be made more compelling,
safer, or productive, Immersion helps its partners broaden market reach by
making the use of touch feedback as critical a user experience as sight and
sound. Immersion's technology is deployed across personal computing,
entertainment, medical training, automotive, and three-dimensional simulation
markets. Immersion and its wholly-owned subsidiaries hold more than 210 issued
patents worldwide.

ABOUT IMMERSION MEDICAL

Immersion Medical designs, manufactures, and markets computer-based medical
training simulation systems worldwide. The systems integrate proprietary
computer software and tactile feedback robotics to create highly realistic
medical procedure simulations that help train doctors. The company's four key
product lines are the CathSim(R) Vascular Access Simulator, the AccuTouch(R)
Endoscopy Simulator, the AccuTouch Endovascular Simulator, and AccuTouch
Laparoscopic Simulator.

FORWARD LOOKING STATEMENTS

This press release contains "forward-looking statements" that involve risks and
uncertainties, as well as assumptions that, if they never materialize or prove
incorrect, could cause the results of Immersion Corporation and its consolidated
subsidiaries to differ materially from those expressed or implied by such
forward-looking statements.

All statements, other than the statements of historical fact, are statements
that may be deemed forward-looking statements, including any projections of
earnings, revenues, or other financial matters; any statements of the plans,
strategies, and objectives of management for future operations; any statements
concerning the future growth of Immersion Medical; consumer and market
acceptance of force feedback products in general; future development of force
feedback products; proposed products or services; any statements regarding
future economic conditions or performance; statements of belief and any
statement or assumptions underlying any of the foregoing. Immersion's actual
results might differ materially from those stated or implied by such
forward-looking statements due to risks and uncertainties associated with
Immersion's business which include, but are not limited to, delay in or failure
to achieve commercial demand for Immersion's products or a delay in or failure
to achieve the acceptance of force feedback as a critical user experience.

For a more detailed discussion of these factors, and other factors that could
cause the Company's actual results to vary materially, interested parties should
review the risk factors listed in the Company's most current Form 10-K and the
Forms 10-Q for the Company's current fiscal year, which are on file with the



U.S. Securities and Exchange Commission. The forward-looking statements in this
press release reflect the Company's beliefs and predictions as of the date of
this release. The Company disclaims any obligation to update these
forward-looking statements as a result of financial, business or any other
developments occurring after the date of this release.

Immersion, CathSim, and AccuTouch are trademarks of Immersion Corporation.

                                       ###